Ansbert Gadicke has bought stock on 3 days since Jan 2021
10% owner at Aktis Oncology, Inc., and 6 other companies
SEC CIK 0001134655 · Filings on SEC.gov ↗
Ansbert Gadicke's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Companies
- AKTS Aktis Oncology, Inc.10% owner
- HOWL Werewolf Therapeutics, Inc.Former 10% Owner
- TCRR Tcr2 Therapeutics Inc.Director and 10% owner
- ITOS Iteos Therapeutics, Inc.10% owner
- CGEM Cullinan Therapeutics, Inc.Director and 10% owner
- RPTX Repare Therapeutics Inc.10% owner
- HARP Harpoon Therapeutics, Inc.10% owner
Every filing
57 filings since Jan 2021, newest first
Harpoon Therapeutics, Inc.
10% owner
Harpoon Therapeutics, Inc.
10% owner
Harpoon Therapeutics, Inc.
10% owner
Harpoon Therapeutics, Inc.
10% owner
Iteos Therapeutics, Inc.
10% owner
Repare Therapeutics Inc.
10% owner
Cullinan Management, Inc.
Director and 10% owner
About Ansbert Gadicke
Ansbert Gadicke, M.D. is a prominent biotech venture capitalist, founder of MPM Capital in 1992, and current Managing Partner of MPM BioImpact (formerly BioImpact Capital).( He has been the lead investor and board member for successful biopharma companies including BioMarin Pharmaceuticals (NASDAQ: BMRN), Idenix (acquired by Merck), Pharmasset (acquired by Gilead, developer of Hepatitis C cure Sovaldi), Mitobridge (acquired by Astellas), Cullinan Oncology (NASDAQ: CGEM), ElevateBio, and Orna Therapeutics, where he serves as Chairman and Co-Founder.(
Gadicke holds an M.D. from J.W. Goethe University in Frankfurt and conducted research at the Whitehead Institute (MIT), Harvard Biochemistry, and the German Cancer Research Center under Nobel Laureate Harald zur Hausen on HPV16/18, with publications in Nature and Cell.( Prior to MPM, he worked at The Boston Consulting Group. He serves on the Harvard Medical School Board of Fellows and Massachusetts General Hospital Research Advisory Council, and received the 2017 Global Oncology Visionary Award. As a 10% Owner and Director, he has engaged in insider trading at companies like Cullinan Oncology and is linked to recent activity at Aktis Oncology, Inc. (AKTS).(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.